Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Gastrointestinal Stromal Tumors 6Leukemia, Myeloid, Chronic-Phase 4Leukemia 4Neoplasms 2Neoplasm Metastasis 2Melanoma 2Sarcoma 1Relapsed Pediatric Solid Tumor 1Mesothelioma 1Meningioma 1Leukemia, Myeloid 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1GIST 1Drug-Related Side Effects and Adverse Reactions 1Chordoma 1Central Nervous System Neoplasms 1Carcinoma, Adenoid Cystic 1Brain Neoplasms 1

Interventions

Protons 2palbociclib 1camrelizumab 1apatinib 1Panobinostat 1Mastectomy, Segmental 1Imatinib Mesylate 1Gelclair 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Chordoma × Imatinib Mesylate × Clear all
NCT01175109 2012-12-27

Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

University of Virginia

Phase 1 Unknown
36 enrolled
Sarcoma

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡